# RNN 1st Gen Model AbbVie Inc. Pharmaceutical preparations
at 20-apr-2018
-
Top 20 Accuracy
ABBV
Model's trade recommendations -17.28% Return for period
5.96% Annual return
$149.78B Market Cap
β 1.61
ABBV
Model (following trade recommendations)ABBV
Underlying stockS&P 500
Index- 3.84 (4.07%) Div (Yield)
- BUY Analysts consensus recommendation
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.
Industry sector: Medical
Sector classification: Pharmaceutical preparations
Deep Learning based analysis and prediction model for AbbVie Inc. (ABBV) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since April 29, 2015.
Market data for ABBV model training are being downloaded from the Quandl premium datasets on a daily basis.
Model is being retrained on a daily basis.
| Float | 1587M |
| P/E | 16.87 |
| Shares Outstanding | 1588M |
| % Held by Insiders | 0.07% |
| % Held by Institutions | 70.57% |
| EPS (last reported FY) | $5.60 |
| EPS (last reported Q) | $1.48 |
| EPS, estimated (last reported Q) | $1.44 |
| Total revenues | $28 B |
| Net income | $5 B |